KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Other Operating Expenses (2017 - 2025)

Travere Therapeutics' Other Operating Expenses history spans 15 years, with the latest figure at $2.6 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed 0.0% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $10.3 million, down 85.83%, while the annual FY2025 figure was $10.3 million, 85.83% down from the prior year.
  • Other Operating Expenses reached $2.6 million in Q4 2025 per TVTX's latest filing, up from $1.6 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $66.7 million in Q1 2024 to a low of -$25.0 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is $4.4 million, with a median of $1.8 million recorded in 2024.
  • Peak YoY movement for Other Operating Expenses: surged 1953.62% in 2021, then crashed 274.05% in 2022.
  • A 5-year view of Other Operating Expenses shows it stood at -$25.0 million in 2021, then soared by 103.47% to $868000.0 in 2022, then skyrocketed by 425.81% to $4.6 million in 2023, then crashed by 44.06% to $2.6 million in 2024, then changed by 0.0% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Operating Expenses are $2.6 million (Q4 2025), $1.6 million (Q3 2025), and $1.5 million (Q2 2025).